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Introduction
In current clinical practice, the biological behaviour
of soft tissue sarcoma tumors is best predicted on the
basis of size and histological grade as determined by
mitotic index, cellularity, necrosis, and the degree of
nuclear anaplasia. Such parameters have been found
to be useful prognostic indicators for survival in soft
tissue sarcoma of the extremities.1 However, in some
cases there is signi￿ cant disagreement among expert
pathologists  in  the  typing  and  grading  of  these
tumors, and as a result, the accurate diagnosis of soft
tissue sarcomas remains a clinical challenge.2–4 Many
of these tumors are quite large and only small frac-
tions are sampled for histopathology. These limita-
tions of histopathology, as well as the need to pursue
new  prognostic  and  treatment  selection  factors,
provide the rationale for a search for more accurate
and less subjective approaches in the diagnosis of soft
tissue sarcoma.
New and advanced methods are becoming increas-
ingly  useful in identifying new prognostic markers
that  could guide the management of patients with
soft tissue sarcoma. These include cytogenetic and
molecular  detection  of  chromosome  translocation
and  gene  fusions.2,5,6 These  techniques  are  still 
experimental and only available in a small number of
centers. Another modality with enormous diagnostic
potential  is  magnetic  resonance  spectroscopy
(MRS).
To date, most of the magnetic resonance reports
on soft tissue sarcoma have dealt with imaging, with
little emphasis on spectroscopy. Magnetic resonance
imaging  (MRI) has proven to be more useful than
CT because of its superior soft tissue contrast and
multiplanar imaging capability, and it is now consid-
ered to be the imaging technique of choice for soft
tissue  masses.7–9 It  has  been  successfully  used  in
radiotherapy treatment planning and tumor volume
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Purpose: Histological grading is currently one of the best predictors of tumor behavior and outcome in soft tissue sarcoma.
However, occasionally there is signi￿ cant disagreement even among expert pathologists. An alternative method that gives
more reliable and non-subjective diagnostic information is needed.The potential use of proton magnetic resonance spec-
troscopy in combination with an appropriate  statistical classi￿ cation strategy was tested here in differentiating normal
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the conventional peak area ratios and a speci￿ c statistical classi￿ cation strategy.
Results: The statistical classi￿ cation strategy gave much better results than the conventional analysis.The overall classi￿ ca-
tion accuracy (based on the histopathology of the MRS specimens) in differentiating normal mesenchymal from soft tissue
sarcoma was 93%, with a sensitivity of 100% and speci￿ city of 88%.The results in the test set were 83, 92 and 76%, respec-
tively. Our optimal region selection algorithm identi￿ ed six spectral regions with discriminating potential, including those
assigned to choline, creatine, glutamine, glutamic acid and lipid.
Conclusion: Proton magnetic resonance spectroscopy combined with a statistical classi￿ cation strategy gave good results in
differentiating normal mesenchymal tissue from soft tissue sarcoma specimens ex vivo. Such an approach may also differ-
entiate benign tumors from malignant ones and this will be explored in future studies.
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DOI: 10.1080/1357714021000065396estimation  in  soft  tissue  sarcomas.10 However, its
diagnostic  speci￿ city  remains  inadequate. For
example, MRI cannot reliably  distinguish between
benign  and  malignant  soft  tissue  sarcomas — well
differentiated liposarcomas have a high fat content
and may resemble benign lipomas on MRI images.
Moreover, in￿ ammatory  changes  and  hematoma
could  mimic  a  tumor  in  an  MRI  image. This,
however, is a lesser problem with MRS.
Magnetic resonance spectroscopy has the ability to
go  beyond  anatomical/morphological  information
and probe the biochemistry of tissues at the cellular
level. Clinical issues regarding tumor aggressiveness,
metastasis and recurrence may be addressed better
by  spectroscopic investigation, since the  technique
yields information on the biochemical and metabolic
changes occurring in the tumor during its develop-
ment and growth. Moreover, the problem of under-
sampling in MRS is not as much of a concern as it is
in routine histopathological procedures. Early MRS
work  on  soft  tissue  sarcoma  focussed  on  31P
MRS.11–15 Such studies have generated useful infor-
mation by revealing that spectra of tumors show high
levels of phospholipids and inorganic phosphate, and
low levels of phosphocreatine. In addition, proton-
decoupled 13C MRS study by Singer et al. has shown
a correlation between the fatty acyl chain content and
the histological type and grade of liposarcomas.16
The higher detection sensitivity of  1H relative to
31P and 13C offers a signi￿ cant advantage. However,
the  1H  MRS  studies  performed  on  soft  tissue
sarcoma have so far focussed primarily on liposar-
comas  and  lipomas. Recently, Singer  et  al. have
shown that  a signi￿ cant correlation exists between
the  degree  of  unsaturation  of  fatty  acyl  chains,
obtained  from  two-dimensional  MRS, and  the
mitotic activity, indicator of grade or degree of differ-
entiation, in soft tissue sarcomas.17 However, such
two-dimensional experiments require long  acquisi-
tion times and are  complicated to  perform. Millis 
et al. in their recent work used both one- and two-
dimensional approaches, but they limited their study
to  liposarcomas.18,19 They  found  that  the  NMR-
visible level  of triglyceride correlated with  liposar-
coma  differentiation, with  the  well-differentiated
tumors having the highest level and the dedifferenti-
ated and/or pleomorphic subtypes (most aggressive
and  metastatic  subtype)  having  the  lowest. It  is
worthwhile  to  point  out  here  that  their  1D  data,
performed with the use of magic angle spinning,were
not analyzed by methods such as the one used herein.
Although liposarcomas are amongst the common
types  of  soft  tissue  sarcoma, they  represent  only
about  20%  of  all  soft  tissue  sarcoma. Malignant
￿ brous histiocytoma (MFH), leiomyosarcoma, and
￿ brosarcoma together,account for about 50% of soft
tissue  sarcomas. Thus, some effort  should also  be
directed towards the MRS study of such types of soft
tissue malignancy to determine whether they share
similar spectral characteristics.
One-dimensional  spectra  and  a  sophisticated
statistical  classi￿ cation  strategy  (SCS)  should
provide a simple and more reliable approach to diag-
nosis. One-dimensional MR spectra contain a set of
resonances whose chemical shifts, relative to a stan-
dard, are indicative of the nature of the biochemical
and  metabolic  species  responsible  for  them. The
intensities of such resonances correspond to the rela-
tive amounts of the  species generating the signals.
Although the MR spectral data are rich in informa-
tion  of  potential  diagnostic  and  prognostic  value,
conventional  methods  of  analysis  fail  to  make
complete use of this valuable information. Our statis-
tical classi￿ cation strategy, by virtue of its ability to
utilize all the information in the spectra, provides a
means  of  analyzing  MRS  data  in  a  robust, non-
subjective and reliable manner.This method has been
successfully used in the classi￿ cation of various other
normal/benign and malignant tissue specimens, e.g.,
breast,20 prostate,21,22 colon,23 brain,24 ovary25 and
thyroid.26
The objective of this ex vivo study was to charac-
terize the spectral features indicative of malignancy
that are common to the various histological types of
soft tissue sarcoma. Using the statistical classi￿ cation
strategy, we sought to develop a robust MRS-based
classi￿ er that can be reliably used in a clinical setting
to differentiate between normal mesenchymal tissue
and soft tissue sarcoma specimens.
Materials and methods
Soft tissue sarcoma and adjacent normal tissue speci-
mens from  a  tissue bank  at  Mount  Sinai  Hospital
(Toronto), administered by  the  Canadian  National
Sarcoma Group,were employed in the study.The spec-
imens were obtained in accordance with the Canadian
Tri-Council Policy on the use of human tissue for med-
ical research. Consent for the use of the excised tissue
specimen  (anonymized)  was  obtained  from  each
patient.Table 1 shows the breakdown for the various
cases.As can be seen,the major types of soft tissue sar-
coma are well represented. Specimens from both the
tumor and the surrounding normal tissue were pro-
vided  for  each  case. The  normal  specimens  were 
primarily composed of muscle (see Table 1).
Whenever  possible, the  specimens  were  divided
into two or three pieces and spectra obtained from
each piece.Thus,a total of 62 spectra (31 normal and
31 malignant) were acquired.However,the quality of
eight spectra was considered non-optimal, and these
spectra were excluded from the set before the data
were subjected to the SCS. Hence, only 54 spectra
(27  normal, 27  malignant)  were  included  in  the
analysis (see Table 1).
The frozen specimens were thawed, mounted in
small capillary tubes and subjected to MRS at 25°C
as  in Kuesel et  al.,27 using  a  high-resolution 360-
MHz  NMR  spectrometer  (Bruker  Instruments,
Billerica, MA). Acquisition  parameters  included:
98 Bezabeh et al.90° pulse at  8.0 m s; number of scans, 256 or 640
depending on the size of the sample; spectral width
= 5000 Hz; recycle delay = 2.41s; and time domain
data  points, 4K. Immediately  following  the  MRS
experiments, all samples were ￿ xed in 10% buffered
formalin and submitted for histopathological evalua-
tion. The  MR  spectra  were  archived  in  a  Silicon
Graphics Computer, and analyzed by the statistical
classi￿ cation strategy as detailed below.
The resonance areas (intensities) were also deter-
mined  for  the  following  seven  spectral  regions,
using  standard  Bruker  integration  routines. The 
integration  limits  (ppm)  for  these  regions  were
3.94–3.88, 3.44–3.38, 3.30–3.13, 3.07–2.90,
2.54–1.83, 1.83–1.05 and 1.05–0.61. The ratios of
these values for both normal and malignant speci-
mens  were  determined  and  compared  using  the
Student t-test  (P < 0.05; Microsoft Excel  97). For
multiple specimens from the same patient, average
values were used in the comparison. Peak area ratios
are reported as mean ± standard deviation.
For the statistical  classi￿ cation strategy, the MR
spectra were partitioned randomly into a training set
(15 normal, 15 malignant) and a test set (12 normal,
12 malignant) before being subjected to the analysis.
The classi￿ er was developed using the training set
and  its  accuracy  validated  on  the  test  set. Each
magnitude  spectrum was  aligned on the  reference
peak  (p-aminobenzoic  acid)  at  6.81  ppm  and
normalized by dividing every data point by the total
spectral area.The 0.5–4.0-ppm region of each spec-
trum was selected in order to minimize the spectral
artifact created by suppression of the water peak at
4.7 ppm.This region of 550 data points was divided
into 110 equal subregions by averaging ￿ ve consecu-
tive data points. An optimal region selection genetic
algorithm28 was employed to determine the regions
of  interest. The classi￿ cation was performed using
linear discriminant analysis  (LDA) with  the  leave-
one-out (LOO) method on the training set.
Results
Figure 1 shows representative spectra from malignant
￿ brous histiocytoma (MFH) and an adjacent normal
mesenchymal tissue.The major resonances of poten-
tial  diagnostic  interest  are  labeled  as  indicated.
Spectral  resonances were  assigned  via  two-dimen-
sional COSY spectra and by comparison with chem-
ical shift values of standard substances and literature
values.18,19,29The two resonances indicated for crea-
tine, at 3.04 and 3.93 ppm, are due to the –CH3, and
1
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Table 1. Histological data of the soft tissue specimens included in the study
Specimen Normal Malignant
419.001 Muscle —
419.002 Fat, 20% muscle —
420.001 — MFH
420.002 — MFH
433.001 Muscle Liposarcoma
433.002 Muscle, 20% ￿ brous tissue/fat Liposarcoma
438.001 Muscle Leiomyosarcoma
438.002 90% muscle, 10% fat Leiomyosarcoma
438.003 Muscle —
445.002 — *
450.001 75% muscle, 25% fat and ￿ brous tissue MFH
450.002 Muscle MFH with > 95% necrosis
454.001 75% muscle, fat **
454.002 75% muscle, fat and ￿ brous tissue Leiomyosarcoma
462.001 90% muscle, ￿ brous tissue Sarcoma NOSa with > 80% necrosis
462.002 90% muscle, ￿ brovascular tissue Sarcoma NOSa with > 80% necrosis
464.001 Muscle PNST
464.002 Muscle PNST
475.001 Muscle MFH
475.002 Muscle *
482.001 Muscle *
482.002 Muscle *
485.001 — Myxoid liposarcoma
485.002 Muscle Myxoid liposarcoma
485.003 Muscle —
486.001 75% muscle, ￿ brous tissue Myxoid liposarcoma
486.002 Muscle Myxoid liposarcoma
488.001 Muscle Liposarcoma
488.002 Muscle Liposarcoma
554.001 Muscle MFH
554.002 Muscle MFH
a NOS, not otherwise speci￿ ed; —, not included in the analysis due to poor spectral quality; *Spectra were put in the test set.The tumor
bank report and SCS classi￿ er indicated the presence of tumor but histopathological assessment of the tissue subjected to MRS did not.
**Spectrum was put in the test set.Tumor bank report indicated tumor but both the SCS and histopathology did not.–CH2– groups of the compound, respectively.There
are notable differences between the two spectra in
many of the resonances,including those from choline
and creatine. For example, higher levels of creatine
and  lower  levels  of  choline-containing metabolites
are seen in the spectra of the normal tissue compared
to  that  of  the  tumor. However, there may  also be
other potentially useful differences that are too dif￿ -
cult to discriminate by visual inspection, and thus
there is the need for the computerized statistical clas-
si￿ cation approach. It is worthwhile to note here that
spectra obtained from multiple pieces of a specimen
(normal or tumor) were very similar.
Figure 2 shows three representative spectra from
soft tissue sarcomas of different histological types:
MFH, leiomyosarcoma and ￿ brosarcoma.The ratio-
nale for showing this ￿ gure is to underscore the fact
that despite numerous small differences, the spectra
have a similar overall appearance, re￿ ective of their
common malignant property.
Besides  performing  the  SCS-based  analysis, an
attempt was also made to determine whether some of
the spectral intensity ratios could serve as useful diag-
nostic markers, since this method had been used in
earlier studies.30,31The mean values of the ratios (for
both normal and malignant) that showed statistically
signi￿ cant differences are indicated in Table 2, as well
as the P values of the statistical comparison.Although
not listed in Table 2, the sensitivity and speci￿ city for
detecting  soft  tissue  malignancy  were  also  deter-
mined for all these spectral ratios. As can be seen in
Table 2, the best P value was obtained for the 0.9/2.0
spectral  intensity  ratio  resulting  in  a  sensitivity  of
100% and a speci￿ city of 92.8%. It is worthwhile to
note here that there was no test set in this conven-
tional analysis.
An optimal set of six subregions was selected by
our  algorithm  as  having  discriminating  potential.
These  subregions  include  resonances  of  choline,
creatine, glutamine, glutamic  acid, and lipids. The
other  subregion  selected  by  the  algorithm  was  at
~2.63 ppm, for which we currently have no biochem-
ical attribution.
The SCS-based classi￿ er resulted in good classi￿ -
cation  accuracy for  both  the  training  and the  test 
sets. The sensitivity and speci￿ city of the technique
for  detecting  cancer  are  indicated  in  Table  3.
Note here that there was a disagreement between the
initial diagnoses provided by the tumor bank and the
ones obtained from histopathological examination of
the tissue specimens subjected to MRS.There was a
better agreement of the SCS results with the former.
However, we have used the histopathological data to
calculate our classi￿ cation accuracy.
These  preliminary  results  show  that  1H  MRS,
combined with the appropriate statistical classi￿ ca-
tion strategy, gives high overall accuracy, and could
potentially  be used to  distinguish between normal
mesenchymal  tissue  and  malignant  soft  tissue
sarcomas.
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Fig. 1. Proton MR spectra (360 MHz, 25°C) of soft tissue
specimens: (A)  malignant  ￿ brous  histocytoma, (B)  adjacent
normal  tissue  from  the  same  subject. Abbreviations: Chos,
choline-containing  compounds; Cr, creatines; Gln, glutamine;
Glu, glutamic acid; HOD, deuteriated water; Leu, leucine;Val,
valine. Assignments  do  not  imply  that  these  are  the  only
substances contributing to a particular peak.
Fig. 2. Proton  MR spectra (360 MHz, 25°C) of soft tissue
sarcoma of different histological types: (A) malignant ￿ brous
histocytoma, (B)  leiomyosarcoma, and  (C)  ￿ brosarcoma.
Spectral peak assignments are the same as in Fig. 1.Discussion
The 1H MR spectra from soft tissue sarcoma are qual-
itatively similar to those of other tissue types, with
many of the common resonances present. However,
there exist some spectral differences between soft tis-
sue sarcomas and other tissue specimens investigated
in our laboratory.We do not normally observe a sin-
glet at 3.93 ppm attributable to the –CH2– of creatine
in normal and tumor tissue specimens from colon,
prostate, cervix, head and neck.The reason for this is
not  evident  at  the  present  time. However, we  do
observe the other creatine resonance (due to –CH3)
in all the above normal tissue specimens, including
those coming from soft tissue.
Comparing  the  results  obtained  by  the  conven-
tional analysis of spectral ratios and the SCS-based
method  illustrates  three  signi￿ cant  points. First,
unlike  the  SCS, the  conventional  peak  area  ratio
analysis does not generally use a test set.All the data
are treated as the training set.Validating the accuracy
of the classi￿ er on a test set is essential for developing
a robust and reliable diagnostic classi￿ er for clinical
use. Second, overall classi￿ cation accuracy is higher
for the SCS-based classi￿ er than for the conventional
analysis. Third, the  conventional  analysis  looks  at
some preselected resonances/ratios  based on some
prior knowledge,whereas such prior knowledge is not
required for applying the SCS.
The  diagnostic  spectral  regions  selected  by  our
algorithm are consistent with ￿ ndings in other types
of tumors. It is worth emphasizing that these regions
were  selected  by  the  algorithm  without  any  prior
input from the user. The ￿ nding of higher choline
metabolite levels indicates an increase in cell prolifer-
ation and membrane biosynthesis in tumors. Similar
results have been obtained for prostate, brain, breast,
and colon tumors.22,23,30–32 MRS studies done to date
on soft tissue sarcoma show higher levels of triglyc-
erides in normals compared to tumors.Alterations in
cellular lipid composition have been found to play an
important role in determining the metastatic behav-
iour of tumor cells.33The degree of fatty acyl unsatu-
ration is believed to be an important determinant of
the metastatic potential of soft tissue sarcomas.17The
signi￿ cantly higher 0.9/1.3 ratio (P = 0.0001) found
for tumors in our study is consistent with this. The
reduction of creatine, indicative of increased energy
metabolism, is also observed in both brain tumors
and malignant prostate tissue. The selection of glu-
tamic acid as one of the discriminatory regions is also
consistent with other ￿ ndings. Glutamic acid levels
have been found to be signi￿ cantly higher in cancers
of colon and stomach.34
One of the common features of soft tissue sarcomas
such as liposarcomas has been an intense broad lipid
resonance.That is why Millis et al. proposed the use
of magic angle spinning (MAS) to resolve the broad
spectral  resonances  and  obtain  useful  informa-
tion.18,19 Although  such  a  technique, without  any
doubt, improves the spectral resolution, it adds com-
plexity of measurement and sample preparation and
lengthens measurement time. Moreover, a potential
disadvantage of the MAS technique is that it adds
many resonances to an already crowded spectrum,
possibly  decreasing  the  discriminating  power. The
present approach is simple to use, robust, and non-
subjective, since it makes use of a computerized sta-
tistical classi￿ cation strategy.One of the advantages of
MAS, however, has been in the resolution of the res-
onance at 3.21 ppm due to choline-containing com-
pounds.This broad peak consists of resonances from
choline, phosphocholine, glycerophosphocholine,
and phosphatidylcholine. Some of these resonances
play a larger role than others in the development and
growth of the tumor and,thus,the resolution of these
resonances and  their  relative  contribution may  be
necessary for a thorough understanding of the bio-
chemical changes associated with malignancy.
The fact that we were able to include tumors with
different histological types and still obtain high accu-
racy indicates that the spectral differences between
normal  and  malignant  specimens are  much  larger
than  those  among  the  different  histological
types/subtypes. Correlations of spectral features with
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Table 2. Comparison of mean values of 1H MR spectral area ratios in soft tissue sarcoma
Spectral Area Ratio Normal* Malignant*  P value
Mean ± S.D. Mean ± S.D.
0.9/2.0 0.49 ± 0.07 0.73 ± 0.11 0.0000003
1.3/2.0 4.47 ± 0.26 3.31 ± 1.17 0.002
0.9/1.3 0.11 ± 0.02 0.25 ± 0.11 0.0001
3.4/3.9 0.42 ± 0.16 0.87 ± 0.59 0.01
3.2/3.9 3.49 ± 0.97 14.20 ± 9.10 0.005
*Although the total number of spectra used was 54 (27 normal, 27 malignant), the numbers of the averaged values included in the analysis
were 13 and 14 for the normal and malignant specimens respectively.
Table 3. Resultsa of the SCS-based classi￿ cation of 1H MR
spectra in the diagnosis of soft tissue sarcoma
Classi￿ cation  Sensitivity Speci￿ city
accuracy
Training set 100 100 100
Test set 83 92 76
Overall 93 100 88
aBased on the histopathological assessment of the tissue subjected
to MRS.the degree of differentiation and histological types/
subtypes would require a much larger sample size.
The next step in our study is to test whether MRS,
combined with a SCS-based classi￿ er,can differenti-
ate between benign and malignant tumors,a clinically
more relevant issue. Once the spectral patterns  of
normal, benign, malignant (different types) are iden-
ti￿ ed ex vivo using the SCS, such information will be
used in an in vivo setting. Ultimately, the objective is
the development of a non-invasive and non-subjective
technique to accurately diagnose the histological type,
the grade and the stage of soft tissue sarcoma.Besides
improving our ability to prognosticate, it should also
be helpful in identifying patients who could bene￿ t
from adjuvant therapy.The fact that 50% of soft tis-
sue sarcomas tend to arise in the extremities,i.e.,MR-
accessible sites, and remain localized to the region 
of origin in the majority of patients,makes them ideal
targets  for  localized  in  vivo MR  spectroscopy.
Potentially, MRS in vivo can be a useful tool in the
diagnosis, prediction of prognosis, choice of therapy,
outlining the exact margin of tumors,and monitoring
of treatment.The types of sequences and parameters
used for different purposes in MRI of soft tissue sar-
coma are discussed at length by Hanna and Fletcher.9
For spectroscopy,one would need to use phased array
coils  and  the  PRESS  sequence  for  spectroscopic
localization35 to obtain good quality spectra from the
volume of interest. Although other coils can be used
for the same purpose, the use of phased array coils is
recommended to maximize the signal.In vivo 31P MR
spectroscopy has already been attempted in soft tis-
sue sarcomas and the results have been promising.12
In fact, soft tissue sarcoma is one of the few types of
cancer that is currently being investigated in an ongo-
ing multi-institutional trial involving nine centers of
localized in vivo 31P MR spectroscopy in human can-
cer research.36A similar effort should also be directed
towards the use of  1H MRS. Since both MRI and
MRS can be performed using the same instrument,
this could easily be combined with a regular MRI
examination.
Acknowledgements
We would like to thank Dr. Irene Andrulis of Mount
Sinai Hospital (Toronto) for her help in obtaining the
tissue specimens.We are very grateful to the Canadian
National  Sarcoma  Group  for  letting  us  use  tissue 
specimens from their bank.This work was presented
in part at the following meetings: International Soc-
iety of Magnetic Resonance in Medicine (Glasgow,
Scotland, May  2001)  and  American  Society  of
Clinical Oncology (San Francisco, California, May
2001).
References
1. Singer S,Corson JM, Gonin R, et al. Prognostic factors
predictive of survival and local recurrence for extremity
soft tissue sarcoma. Ann Surg 1994; 219: 165–73.
2. Singer S. New diagnostic modalities in soft tissue sar-
coma. Semin Surg Oncol 1999; 17: 11–22.
3. Alvegard TA, Berg NO. Histopathology peer review of
high-grade soft tissue sarcoma:The Scandinavian sar-
coma group experience.J Clin Oncol 1989;7:1845–52.
4. Coindre  JM, Trojani  M, Contesso  G, et  al.
Reproducibility of a histopathologic grading system for
adult soft tissue sarcoma. Cancer 1986; 58: 306–9.
5. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl
Surg 1996; 33: 820–72.
6. Levine EA. Prognostic factors in soft tissue sarcoma.
Semin Surg Oncol 1999; 17: 23–32.
7. Heslin MJ, Smith JK. Imaging of soft tissue sarcoma.
Surg Oncol Clin North Am 1999; 8: 91–107.
8. Massengill AD,Seeger LL,Eckardt JJ,et al.The role of
plain  radiography, computed tomography, and  mag-
netic resonance imaging in sarcoma evaluation.Hematol
Oncol Clin North Am 1995; 9: 571–604.
9. Hanna SL,Fletcher BD.MR Imaging of malignant soft
tissue tumors.Magn Reson Imaging Clin North Am 1995;
3: 629–50.
10. Varma DGK, Jackson EF, Pollock RE, et al. Soft-tissue
sarcoma of the extremities: MR appearance of post-
treatment changes and local recurrences. Magn Reson
Imaging Clin North Am 1995; 3: 695–712.
11. Negendank  WG,Crowley MG,Ryan JR,et al.Bone and
soft-tissue lesions: diagnosis with combined H-1 MR
imaging and P-31 MR spectroscopy. Radiology 1989;
173:181–6.
12. Negendank WG. MR spectroscopy of musculoskeletal
soft-tissue tumors. Magn Reson Imaging Clin North Am
1995; 3: 713–25.
13. Shinkwin MA,Lenkinski RE,Daly JM,et al. Integrated
magnetic  resonance  imaging  and  phosphorus  spec-
troscopy  of  soft  tissue  tumors. Cancer  1991; 67:
1849–58.
14. Sostman HD, Prescott DM, Dewhirst MW, et al. MR
imaging and spectroscopy for prognostic evaluation in
soft-tissue sarcomas. Radiology 1994; 190: 269–75.
15. Redmond OM,Bell E,Stack JP, et al.Tissue character-
ization and assessment of musculoskeletal tumors by in
vivo 31P magnetic resonance spectroscopy.Magn Reson
Med 1992; 27: 226–37.
16. Singer S, Millis K, Souza K et al. Correlation of lipid
content and  composition with  liposarcoma  histology
and grade. Ann Surg Oncol 1997; 4: 557–63.
17. Singer  S, Sivaraja  M, Souza  K, et  al. 1H-NMR
detectable  fatty  acyl  chain  unsaturation  in  excised
leiomyosarcoma correlate with grade and mitotic activ-
ity. J Clin Invest 1996; 98: 244–50.
18. Millis KK, Mass WE, Cory DG, et al. Gradient, high-
resolution, magic-angle spinning nuclear magnetic res-
onance spectroscopy of human adipocyte tissue. Magn
Reson Med 1997; 38: 399–403.
19. Millis K,Weybright P, Campbell N, et al. Classi￿ cation 
of  human  liposarcoma  and  lypoma  using  ex  vivo
proton nmr spectroscopy. Magn Reson Med 1999; 41:
257–67.
20. Mountford  CE, Somorjai  RL, Malycha  P, et  al.
Diagnnosis and prognosis of breast cancer by magnetic
spectroscopy of ￿ ne-needle aspirates analysed using a
ststistical  classi￿ cation strategy. Br  J  Surg 2001; 88:
1234–40.
21. Hahn P,Smith ICP,Leboldus L,et al.The classi￿ cation
of benign and malignant human prostate tissue by mul-
tivariate  analysis  of  1H  magnetic  resonance  spectra.
Cancer Res 1997; 57: 3398–401.
22. Menard C, Smith ICP, Somorjai RL, et al. Magnetic
resonance spectroscopy of the malignant prostate gland
after radiotherapy: a histopathological  study of diag-
nostic validity. Int J Radiat Oncol Biol Phys 2001; 50:
317–23.
102 Bezabeh et al.1
1
1
Proton magnetic resonance spectroscopy of soft tissue sarcoma 103
23. Bezabeh T, Smith ICP, Krupnik E, et al. Diagnostic
potential for cancer via 1H magnetic resonance spec-
troscopy  of  colon  tissue. Anticancer  Res  1996; 16:
1553–8.
24. Somorjai  RL, Dolenko  B, Nikulin  AK, et  al.
Classi￿ cation  of  1H  MR  spectra  of  human  brain
neoplasms:the in￿ uence of preprocessing and comput-
erized consensus diagnosis on classi￿ cation accuracy. J
Magn Reson Imaging 1996; 6: 437–44.
25. Wallace  JC, Raaphorst  GP, Somorjai  RL, et  al.
Classi￿ cation  of  1H  MR  spectra  of  biopsies  from
untreated and  recurrent ovarian  cancer  using  linear 
discriminant  analysis. Magn  Reson  Med  1997; 38:
569–76.
26. Somorjai RL, Nikulin AE, Pizzi N,et al. Computerized
consensus  diagnosis: a  classi￿ cation  strategy  for  the
robust  analysis  of  MR  spectra. I. Application  to  1H
spectra of thyroid neoplasms. Magn Reson Med 1995;
33: 257–63.
27. Kuesel AC,Kroft T,Saunders JK,et al.A simple proce-
dure for obtaining high-quality NMR spectra of semi
quantitative value from small tissue specimens:cervical
biopsies. Magn Reson Med 1992; 27: 340–55.
28. Nikulin AE, Dolenko B, Bezabeh T, et al. Near-optimal
region  selection  for  feature  space  reduction: novel-
preprocessing  methods  for  classifying  MR  spectra.
NMR Biomed 1998; 11: 209–17.
29. Sze DY, Jardetzky O. Characterization of lipid compo-
sition in stimulated human lymphocytes by 1H-NMR.
Biochim Biophys Acta 1990; 1054: 198–206.
30. Lean CL, Newland RC, Ende DA, et al. Assessment of
human  colorectal  biopsies  by  1H  MRS: correlation 
with histopathology.Magn Reson Med 1993;30:525–33.
31. Mackinnon WB, Barry PA, Malycha PL, et al. Fine-
needle  biopsy  specimens  of  benign  breast  lesions
distinguished from invasive cancer ex vivo with proton
MR spectroscopy. Radiology 1997; 204: 661–6.
32. Daly PF, Lyon RC, Faustino PJ, et al. Phospholipid
metabolism  in  cancer  cells  monitored  by  31P  NMR
spectroscopy. J Biol Chem 1987; 31: 14875–78.
33. Dahiya  R, Boyle B, Goldberg BC, et al. Metastasis-
associated alterations in phospholipids and fatty acids
of human prostatic adenocarcinoma cell lines. Biochem
Cell Biol 1992; 70: 548–54.
34. Okada A,Takehara H,Yoshida K, et al. Increased aspar-
tate  and  glutamate  levels  in  both  gastric  and  colon
cancer tissues. Tokushima J Exp Med 1993; 40: 19–25.
35. Bottomley  PA. Spatial  localization  in  NMR  spec-
troscopy. Ann NY Acad Sci 1987; 508: 333-48.
36. Arias-Mendoza  F, Brown  TR, Charles  HC, et  al.
Methodological  standardization  for  a  multi-institu-
tional in vivo trial of localized 31P MR spectroscopy in
human cancer research. Proc Int Soc Mag Reson Med
1999; 7: 1585 (Abstr).